RE:RE:RE:RE:RE:RE:More consolidation in US health care
Newfinvest wrote: A portion of the offering will be allocated to marketing Aristotle. What that number is we do not know... but it needs to be fairly significant as marketing effectively is not cheap. As stated previously, with this coupled with some profits realized from increased covid tests I would hope an effective marketing campaign can be rolled out sooner than later.... I will add this however, I am not certain that 10000 patients is enough for validation and more may be required. We are ahead of the field as those already have been validated... if more is required for acceptance then how many more and what time line? In my opinion there needs to be a partnership with a medical center or centers... ichor saying they offer the service is great as it is a glimpse of good news... some news... on Aristotle being used and available. Time to stand up and lay it out Tripp. I hope the call at 8am Jan 7 provides additional insight and we get 2021 rolling in a positive direction.
the 10000 test seem to be a minimum to show data after clinical trials, same thing with Thrive who tested 10000 women for clinical trial and then showed their data last year.
Like any other bio company they will do further tests but in the meanwhile we are focusing in the launch of ARISTOTLE wich is essential to be a Leader in this field.
Things are getting better and cashflow from Covid will be significant to the imvestment into Aristotle launch!
Let we not forget we have insider who already have set foot in Nasdaq bio company as insider aswell so........many scenario in my mind lol